MAIA

MAIA Biotechnology, Inc. (MAIA) - 10-Q Summary

Business Context and Reporting Period

Company: MAIA Biotechnology, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: MAIA is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. Its lead asset, ateganosine (THIO), is an investigational dual mechanism of action drug candidate targeting telomeres and immunogenicity, primarily for Non-Small Cell Lung Cancer (NSCLC). The company operates in a single segment and has no product revenue.

Key Financial Metrics

Cash Flow (Six Months Ended June 30, 2026):
- Net cash used in operating activities: $(12,061,383)
- Net cash provided by financing activities: $30,987,321
- Net increase in cash: $18,937,800

Material Changes vs. Prior Period

• Operating Expenses: Increased by 44% ($4.68 million) year-over-year. Research and Development (R&D) expenses rose 45% to $9.16 million, driven by increased clinical and scientific research costs. General and Administrative (G&A) expenses rose 42% to $6.10 million, primarily due to higher investor relations and payroll costs.
• Net Loss: Increased by 45% to $14.31 million, reflecting higher operating costs partially offset by other income.
• Liquidity: Cash balances increased significantly from $8.66 million at year-end 2025 to $27.60 million at June 30, 2026, following a major equity raise.
• Other Income: Net other income increased to $953,941 (from $727,267), driven by $420,738 in grant income and $348,077 in interest income, offset by a $185,126 gain on the change in fair value of warrant liability.

Guidance, Outlook, and Risks

Capital Raise: In March 2026, the company completed a confidentially marketed public offering, selling approximately 22 million shares for gross proceeds of ~$33 million. Management stated these proceeds are expected to fully fund the ongoing pivotal Phase 3 clinical trial (THIO-104).

Clinical Progress:

• Phase 3 (THIO-104): Ongoing for advanced 3L NSCLC; 29 patients dosed as of June 4, 2026.
• Phase 2 (THIO-101): International enrollment for Part C completed; U.S. expansion initiated with three sites activated. Initial efficacy results (July 2026) showed a 90.5% disease control rate in evaluable patients.
• Future Trials: Plans to initiate Phase 2 trials in HCC, CRC, and SCLC in 2026 in collaboration with BeOne Medicines.

Risks and Contingencies:

• Liquidity Risk: The company has an accumulated deficit of $123.9 million and expects to continue incurring losses. Future operations depend on raising additional equity or debt financing.
• Legal Proceedings: H.C. Wainwright & Co. filed a lawsuit in April 2026 alleging breach of a right of first refusal regarding the March 2026 offering, seeking ~$2.3 million in cash and warrants. The company filed a motion for dismissal in June 2026.
• Regulatory Risk: Accelerated approval for ateganosine is targeted for 2026, but there is no guarantee of FDA approval or accelerated review.
• Digital Assets: A Digital Asset Treasury Plan was adopted in October 2025 to hold Bitcoin/Ether, but the strategy is currently on hold, and no assets have been purchased.

Investor Verification Checklist

• Cash Runway: Verify if the $27.6 million cash balance is sufficient to fund the Phase 3 trial through completion given the $12 million operating cash burn in six months.
• Legal Outcome: Monitor the status of the Wainwright lawsuit and potential settlement costs or warrant issuance.
• Clinical Data: Review the full data release from the Phase 2 THIO-101 trial (July 2026) to assess the 90.5% disease control rate and its implications for regulatory filing.
• Financing Needs: Assess the likelihood of needing additional capital before commercial approval, considering the company's history of frequent private placements and ATM offerings.
• Warrant Liability: Monitor the fair value of the $1.3 million warrant liability, as fluctuations impact net income/loss.